Literature DB >> 11943523

Clinical properties of levobupivacaine or racemic bupivacaine for sciatic nerve block.

Andrea Casati1, Jacques E Chelly, Elisa Cerchierini, Roberta Santorsola, Fiorella Nobili, Crispino Grispigni, Pia Di Benedetto, Giorgio Torri.   

Abstract

STUDY
OBJECTIVE: To compare the intraoperative and postoperative clinical properties of the sciatic nerve block performed with either 0.5% bupivacaine or 0.5% levobupivacaine for orthopedic foot procedures.
DESIGN: Randomized, double-blind study.
SETTING: Inpatient unit of a university-affiliated hospital. PATIENTS: 30 ASA physical status I and II patients undergoing elective hallux valgus repair under regional anesthesia.
INTERVENTIONS: After administering intravenous (IV) midazolam premedication (0.05 mg/kg), a femoral nerve block was performed with 15 mL of mepivacaine 2%. Patients were then randomly allocated to receive, in a double-blind fashion, a sciatic nerve block with 20 mL of either 0.5% bupivacaine (n = 15) or 0.5% levobupivacaine (n = 15).
MEASUREMENTS AND MAIN RESULTS: An observer who was blinded to the study drug recorded the onset time, quality, and duration of the sciatic nerve block. Postoperative analgesia consisted of 100 mg IV ketoprofen every 8 hours, with the first administration given at the patient's request. Mean (+/-SEM) onset time of the sciatic nerve block was 35 +/- 5 minutes for bupivacaine and 31 +/- 6 minutes for levobupivacaine (p = not significant [NS]). The duration of motor and sensory blocks with bupivacaine was 761 +/- 112 minutes and 790 +/- 110 minutes, respectively, and 716 +/- 80 minutes and 814 +/- 73 minutes, respectively, with levobupivacaine (p = NS). The first pain medication was requested after 844 +/- 96 minutes with bupivacaine and 872 +/- 75 minutes after levobupivacaine (p = NS). No differences in the quality of nerve block and patient satisfaction were reported between the two groups.
CONCLUSIONS: A dose of 20 mL of 0.5% levobupivacaine induces sciatic nerve block of similar onset, duration, and intensity as the block produced by the same volume and concentration of the racemic solution of bupivacaine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943523     DOI: 10.1016/s0952-8180(01)00364-6

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  7 in total

Review 1.  [Levobupivacaine for regional anesthesia. A systematic review].

Authors:  B Urbanek; S Kapral
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

2.  Lipid emulsion mitigates local anesthesia-induced central nervous system toxicity in rats.

Authors:  Gangming Wu; Bin Sun; L I Liu; Jun Zhou; Liqun Mo; Changhe Ren; Cehua Ou
Journal:  Exp Ther Med       Date:  2015-06-24       Impact factor: 2.447

3.  Evaluation of the effects of ketamine on spinal anesthesia with levobupivacaine or ropivacaine.

Authors:  Yan Zhang; Hong Lin; Wen-Bo Yi
Journal:  Exp Ther Med       Date:  2016-08-10       Impact factor: 2.447

4.  Levobupivacaine vs. bupivacaine for third molar surgery: quality of anaesthesia, postoperative analgesia and local vascular effects.

Authors:  Denis Brajkovic; Bozidar Brkovic; Marija Milic; Vladimir Biocanin; Elena Krsljak; Dragica Stojic
Journal:  Clin Oral Investig       Date:  2013-10-06       Impact factor: 3.573

5.  Efficacy and safety of 1% ropivacaine for postoperative analgesia after lower third molar surgery: a prospective, randomized, double-blinded clinical study.

Authors:  Božidar Brković; Miroslav Andrić; Dejan Ćalasan; Marija Milić; Jelena Stepić; Milan Vučetić; Denis Brajković; Ljubomir Todorović
Journal:  Clin Oral Investig       Date:  2016-04-25       Impact factor: 3.573

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine.

Authors:  Chantal A A Heppolette; Derek Brunnen; Sohail Bampoe; Peter M Odor
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

7.  Update on local anesthetics: focus on levobupivacaine.

Authors:  Crina L Burlacu; Donal J Buggy
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.